当前位置: X-MOL 学术Hepatology › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial
Hepatology ( IF 13.5 ) Pub Date : 2022-08-22 , DOI: 10.1002/hep.32742
Chin Wong 1 , Ajit Dash , Jill Fredrickson , Nicholas Lewin-Koh , Shan Chen , Kenta Yoshida , Yanqiu Liu , Johnny Gutierrez , Rebecca Kunder
Affiliation  

BFKB8488A is a bispecific antibody targeting fibroblast growth factor receptor 1c and Klothoβ. This phase 1b study assessed safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of BFKB8488A in patients with type 2 diabetes mellitus (T2DM) or NAFLD.

中文翻译:

成纤维细胞生长因子受体 1/Klothoβ 激动剂 BFKB8488A 改善糖尿病或 NAFLD 患者的血脂和肝脏健康指标:1b 期随机试验

BFKB8488A 是一种针对成纤维细胞生长因子受体 1c 和 Klothoβ 的双特异性抗体。这项 1b 期研究评估了 BFKB8488A 在 2 型糖尿病 (T2DM) 或 NAFLD 患者中的安全性、耐受性、药代动力学、免疫原性和药效学。
更新日期:2022-08-22
down
wechat
bug